Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Shares Outstanding (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Shares Outstanding for 8 consecutive years, with $14.0 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Shares Outstanding rose 49.24% year-over-year to $14.0 million, compared with a TTM value of $14.0 million through Jun 2023, up 49.24%, and an annual FY2022 reading of $9.4 million, changed 0.33% over the prior year.
  • Shares Outstanding was $14.0 million for Q2 2023 at Avalo Therapeutics, up from $13.2 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $44.4 million in Q4 2019 and bottomed at $1.3 million in Q1 2020.
  • Average Shares Outstanding over 5 years is $11.0 million, with a median of $9.4 million recorded in 2021.
  • The sharpest move saw Shares Outstanding skyrocketed 2521.5% in 2020, then plummeted 97.89% in 2021.
  • Year by year, Shares Outstanding stood at $44.4 million in 2019, then plummeted by 97.17% to $1.3 million in 2020, then skyrocketed by 647.69% to $9.4 million in 2021, then rose by 0.33% to $9.4 million in 2022, then skyrocketed by 48.85% to $14.0 million in 2023.
  • Business Quant data shows Shares Outstanding for AVTX at $14.0 million in Q2 2023, $13.2 million in Q1 2023, and $9.4 million in Q4 2022.